Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Aged
Albumins
/ therapeutic use
Drug Therapy, Combination
/ methods
Female
Follow-Up Studies
Hepatorenal Syndrome
/ drug therapy
Humans
Kaplan-Meier Estimate
Liver Cirrhosis
/ complications
Liver Transplantation
/ statistics & numerical data
Male
Middle Aged
Recurrence
Remission Induction
/ methods
Terlipressin
/ therapeutic use
Treatment Outcome
Vasoconstrictor Agents
/ therapeutic use
AKI
HRS
albumin
hepatorenal syndrome
liver cirrhosis
terlipressin
Journal
United European gastroenterology journal
ISSN: 2050-6406
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
01
08
2018
accepted:
04
12
2018
entrez:
9
5
2019
pubmed:
9
5
2019
medline:
9
5
2019
Statut:
ppublish
Résumé
Hepatorenal syndrome (HRS) is associated with a poor prognosis. In HRS type 1, loss of renal function is rapidly progressive, while HRS type 2 is characterised by chronic ascites and more moderately elevated renal parameters. While treatment with terlipressin/albumin is well established in type 1, its effectiveness in chronic HRS is less clear. The aim of this study was to evaluate the effectiveness of terlipressin/albumin treatment in patients with HRS type 2. All patients with a first episode of HRS between April 2013 and February 2016 were included in this observational study. Relevant clinical and laboratory parameters were recorded and patients were followed. A total of 106 patients with HRS were included. With terlipressin therapy reversal of HRS types 1 and 2 was achieved in 48% and 46% of patients ( A terlipressin treatment course seems to be justified in selected patients with HRS type 2, especially in countries and settings with long transplant waiting lists. In addition treatment response might also help to identify HRS type 2 patients with a more favourable outcome.
Sections du résumé
Background
Hepatorenal syndrome (HRS) is associated with a poor prognosis. In HRS type 1, loss of renal function is rapidly progressive, while HRS type 2 is characterised by chronic ascites and more moderately elevated renal parameters. While treatment with terlipressin/albumin is well established in type 1, its effectiveness in chronic HRS is less clear.
Objective
The aim of this study was to evaluate the effectiveness of terlipressin/albumin treatment in patients with HRS type 2.
Methods
All patients with a first episode of HRS between April 2013 and February 2016 were included in this observational study. Relevant clinical and laboratory parameters were recorded and patients were followed.
Results
A total of 106 patients with HRS were included. With terlipressin therapy reversal of HRS types 1 and 2 was achieved in 48% and 46% of patients (
Conclusion
A terlipressin treatment course seems to be justified in selected patients with HRS type 2, especially in countries and settings with long transplant waiting lists. In addition treatment response might also help to identify HRS type 2 patients with a more favourable outcome.
Identifiants
pubmed: 31065370
doi: 10.1177/2050640619825719
pii: 10.1177_2050640619825719
pmc: PMC6488797
doi:
Substances chimiques
Albumins
0
Vasoconstrictor Agents
0
Terlipressin
7Z5X49W53P
Banques de données
DRKS
['DRKS00013117']
Types de publication
Journal Article
Observational Study
Langues
eng
Pagination
529-537Références
Int Urol Nephrol. 2011 Mar;43(1):175-84
pubmed: 20306131
Hepatology. 1996 Jan;23(1):164-76
pubmed: 8550036
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Hepatol. 2007 Oct;47(4):499-505
pubmed: 17560680
J Hepatol. 2008;48 Suppl 1:S93-103
pubmed: 18304678
Hepatology. 2013 Apr;57(4):1651-3
pubmed: 23463403
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
J Gastroenterol Hepatol. 2008 Oct;23(10):1535-40
pubmed: 17784863
Hepatology. 2002 Oct;36(4 Pt 1):941-8
pubmed: 12297842
Am J Transplant. 2017 Jun;17(6):1447-1454
pubmed: 28066980
Gastroenterology. 1993 Jul;105(1):229-36
pubmed: 8514039
Liver Int. 2013 Jan;33(1):16-23
pubmed: 22507181
Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1363-8
pubmed: 12468959
Liver Int. 2013 Sep;33(8):1187-93
pubmed: 23601499
Dig Dis Sci. 2008 Mar;53(3):830-5
pubmed: 17939047
Lancet. 2003 Nov 29;362(9398):1819-27
pubmed: 14654322
Liver Int. 2018 Apr;38(4):570-580
pubmed: 28921803
Liver Int. 2006 Sep;26(7):834-9
pubmed: 16911466
Liver Transpl. 2015 Nov;21(11):1347-54
pubmed: 26178066
Gastroenterology. 2008 May;134(5):1360-8
pubmed: 18471513
J Gastroenterol Hepatol. 2003 Feb;18(2):152-6
pubmed: 12542598
J Hepatol. 2015 Apr;62(4):968-74
pubmed: 25638527
Gastroenterology. 2002 Apr;122(4):923-30
pubmed: 11910344
Gut. 2007 Sep;56(9):1310-8
pubmed: 17389705
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005162
pubmed: 17054242
J Hepatol. 2012 Jun;56(6):1293-8
pubmed: 22322237
J Hepatol. 2000 Jul;33(1):43-8
pubmed: 10905585
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD005162
pubmed: 22972083